Peptide Profile
Foxo4-DRI
Foxo4-D-Retro-Inverso · Proxofim · Senolytic peptide
FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated…
- Half-life
- Unknown
- Routes
- intravenous, subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Foxo4-DRI is
About Foxo4-DRI
D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"
FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant. The foundational study published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo in mice, restoring tissue homeostasis in both chemotherapy-induced and naturally aged animals; subsequent molecular modeling work has characterized the FOXO4-TP53 interaction interface to guide further senolytic peptide design, though published evidence in humans is absent and the preclinical literature remains limited. FOXO4-DRI is a research compound with no regulatory approval in any jurisdiction; it has been studied only in preclinical animal models, and no human pharmacokinetic, safety, or clinical efficacy data has been established.
Foxo4-DRI Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
What the evidence says about Foxo4-DRI
Research Evidence
based on 3 studies · most recent 2026
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
3 sources cited · 3 weak
1 Review · 2 Animals
Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-TP53 protein-protein interaction
EBioMedicine · 2021
Research applying rational peptide design principles to the FOXO4-TP53 interaction produced the ES2 senolytic variant, which selectively cleared p53-high senescent cancer and aged liver cells in mouse models while leaving non-senescent cells intact, extending the therapeutic framework established for FOXO4-DRI.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Cell · 2017
This landmark study demonstrated that FOXO4-DRI, a rationally designed peptide that disrupts the FOXO4-p53 interaction in senescent cells, induced selective apoptosis of senescent cells in aged mice, restoring physical fitness, fur density, and renal function while sparing non-senescent cells, establishing proof-of-concept for peptide-based senolytic therapy.
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Naunyn Schmiedebergs Arch Pharmacol · 2026
# Summary Research found that FOXO4-DRI, a senolytic peptide designed to disrupt the FOXO4-p53 complex, selectively eliminates senescent cells in the brain while preserving healthy tissue, thereby reducing accumulation of aging cells and restoring blood-brain barrier integrity, cerebral blood flow, and cognitive function in aged animal models. This study demonstrated that targeting the FOXO4-p53 axis represents a potential pharmacological strategy to address age-related cognitive decline and neurodegenerative conditions by reducing neuroinflammation, synaptic dysfunction, and impaired neurogenesis associated with cellular senescence in the aging brain.
Foxo4-DRI Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Absolute contraindications
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSFoxo4-DRI
Third-party testing data
Limited testing data (1 verified result)
We only show a verified-testing signal once at least 3 independent lab results are on file. Below that, we show what we have without implying a confidence signal.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Certificates of Analysis
- Confirmed by labLimitless Peptides
Foxo4-DRI · Jan 30, 2026 · View source COA
99.8%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Frequently Asked Questions — Foxo4-DRI
FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant.
senescent cell clearance, tissue rejuvenation, healthspan extension, senolytic.
Research on Foxo4-DRI primarily documents effects related to senescent cell clearance and tissue rejuvenation and healthspan extension and senolytic. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Foxo4-DRI, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
10 providers in the directory currently offer Foxo4-DRI.
Across 17 research vendors tracked on PeptideBase, Foxo4-DRI has a median price of about $22.00 per mg, typically ranging $10.23–$24.50 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
How to get Foxo4-DRI
Market Pricing
17 vendorsPrice per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified August 2026 · Foxo4-DRI price intelligence
Where to buy Foxo4-DRI
10 providersQuestions to ask your provider
Stay updated on Foxo4-DRI providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Foxo4-DRI — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/foxo4-dri